|Description||Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.|
|B0084-069824||5 g||$288||In stock|
|Synonyms||BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis|
BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa with Ki of 0.03 nM.
Otamixaban, is a novel, selective, rapid acting, competitive, reversible and direct fXa inhibitor of the β-aminoester class. It was in Phase-III clinical develo...
Edoxaban TsOH salt
Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.
Eribaxaban is an orally active inhibitor of coagulation factor Xa (activated factor X). It has anticoagulant activity and is used as an anticoagulant drug. It i...
Betrixaban is a long-acting anticoagulant used for the treatment of venous thromboembolism (VTE) caused by limited mobility or some other factors in adult patie...
BMS-344577 is aroylguanidine-based lactam derivative, which is a potent FXa inhibitor (FXa IC(50)=4 nM, EC(2xPT)=7 microM).
Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembol...
Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a...